Analyst Reco. HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
0.8 ^USD	-23.08%		-1.89%	-1.23%

May. 23	HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting	CI
May. 09	HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on HOOKIPA Pharma to $5 From $6 Amid Restructuring Plan, Termination of Roche Partnership on KRAS; Outperform, Speculative Risk Kept	Jan. 30	MT
HOOKIPA Pharma Says Head, Neck Cancer Phase 2 Study of Therapy Combination Showed 42% Objective Response Rate	23-10-23	MT
HC Wainwright Adjusts HOOKIPA Pharma Price Target to $6.50 From $8, Maintains Buy Rating	23-08-11	MT
Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $2.25 From $2, Maintains Equal-Weight Rating	23-06-05	MT
Truist Securities Adjusts HOOKIPA Pharma Price Target to $4 From $11, Maintains Buy Rating	23-03-20	MT
RBC Trims Price Target on HOOKIPA Pharma to $7 From $8, Affirms Outperform Rating	22-11-15	MT
Truist Securities Lowers HOOKIPA Pharma's Price Target to $11 From $16, Maintains Buy Rating	22-08-23	MT
SVB Securities Adjusts HOOKIPA Pharma's Price Target to $3 From $4, Keeps Outperform Rating	22-08-12	MT
Kempen Upgrades HOOKIPA Pharma to Buy From Neutral, Lifts Price Target to $3 From $2.60	22-04-01	MT
RBC Cuts Price Target on HOOKIPA Pharma to $9 From $11, Maintains Outperform Rating, Speculative Risk Qualifier	22-03-25	MT
HC Wainwright Adjusts HOOKIPA Pharma Price Target to $8 From $15, Maintains Buy Rating	22-02-17	MT
SVB Leerink Adjusts HOOKIPA Pharma's Price Target to $4 from $3, Maintains Outperform Rating	22-02-16	MT
Kempen Downgrades HOOKIPA Pharma to Neutral From Buy, Adjusts Price Target to $2.60 From $24	21-12-22	MT
Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight From Overweight; Price Target is $6	21-11-12	MT
HC Wainwright Adjusts Price Target on Hookipa Pharma to $15 From $21, Keeps Buy Rating	21-11-11	MT
SVB Leerink Adjusts HOOKIPA Pharma PT to $10 From $28, Maintains Outperform Rating	21-11-10	MT
JMP Securities Adjusts Price Target on HOOKIPA Pharma to $11 From $25, Maintains Market Outperform Rating	21-11-10	MT
RBC Cuts PT on HOOKIPA Pharma to $17 From $24, Citing Program Prioritization, Timeline Updates; Outperform-Speculative Risk Rating Kept	21-11-10	MT
HOOKIPA PHARMA : Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $18 From $19, Maintains Overweight Rating	21-08-18	MT
HOOKIPA PHARMA : HC Wainwright Adjusts HOOKIPA Pharma's Price Target to $21 from $16, Keeps Buy Rating	21-05-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Analyst Reco.

Filters